An Expert Report on Recombinant Human Thrombopoietin (DB16364)

Executive Summary

Recombinant Human Thrombopoietin (rhTPO), identified by DrugBank accession number DB16364, is a full-length, glycosylated recombinant protein that is structurally and functionally analogous to the endogenous cytokine thrombopoietin, the principal physiological regulator of platelet production.[1] Produced in a mammalian Chinese hamster ovary (CHO) cell expression system, rhTPO represents a direct replacement therapy designed to address conditions of thrombocytopenia arising from insufficient platelet production or excessive destruction.[1]

The primary mechanism of action involves the binding and activation of the thrombopoietin receptor (c-Mpl) on the surface of hematopoietic stem cells and megakaryocyte progenitor cells. This interaction initiates a cascade of intracellular signaling pathways, most notably the Janus kinase/signal transducer and activator of transcription (JAK/STAT) and mitogen-activated protein kinase (MAPK) pathways. These signals collectively promote the survival, proliferation, differentiation, and maturation of megakaryocytes, culminating in a rapid and effective increase in the number of circulating platelets.[1]

Extensive clinical investigation, predominantly conducted in China, has substantiated the efficacy of rhTPO in various clinical settings. It has demonstrated significant therapeutic benefit in raising platelet counts and mitigating bleeding risk in patients with Primary Immune Thrombocytopenia (ITP), with established efficacy in adult, pediatric, and pregnant populations.[1] Furthermore, rhTPO is effective in the management of Chemotherapy-Induced Thrombocytopenia (CIT).[7] Clinical evidence suggests that dose optimization, particularly the use of higher doses such as 30,000 U/day, can elicit faster and more robust responses in ITP compared to conventional dosing regimens.[4]

A defining characteristic of rhTPO is its favorable safety and immunogenicity profile. The majority of reported adverse events are mild and transient.[1] Critically, its full-length, glycosylated structure, which closely mimics the native human protein, confers a low immunogenic potential. Clinical studies have detected only the formation of transient, low-titer anti-TPO antibodies that lack neutralizing activity. This safety record stands in stark contrast to earlier, truncated recombinant forms of TPO, such as PEG-rHuMGDF, which were withdrawn from development due to the induction of neutralizing autoantibodies that caused severe thrombocytopenia.[1]

Regarding its regulatory standing, rhTPO, marketed as TPIAO® by 3SBio Inc., has received approval from the National Medical Products Administration (NMPA) in China for the treatment of adult and pediatric ITP, as well as for CIT.[6] Despite its long-term clinical use and established safety record in China, rhTPO is not approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA). In these regions, other thrombopoietin receptor agonists (TPO-RAs), such as the peptibody romiplostim and the small molecule eltrombopag, constitute the standard of care.[13]

In conclusion, rhTPO is a scientifically refined and clinically effective thrombopoietic agent, differentiated within its class by its structural fidelity to endogenous TPO. Its proven efficacy, rapid onset of action, and notably superior safety and immunogenicity profile position it as a particularly valuable therapeutic option for acute clinical settings and in sensitive patient populations. Its market presence, however, remains geographically restricted to China. This suggests that historical regulatory concerns associated with first-generation recombinant TPOs, combined with the entrenched market position of structurally distinct competitors, present formidable barriers to its potential global development and adoption.

1.0 Introduction: The Physiological Role of Thrombopoietin and the Rationale for Recombinant Therapies

The TPO-c-Mpl Axis: The Master Regulator of Thrombopoiesis

The production of platelets, a process known as thrombopoiesis, is a complex and tightly regulated physiological function essential for hemostasis and vascular integrity. At the apex of this regulatory network is the TPO-c-Mpl axis. Thrombopoietin (TPO) is the indispensable cytokine that serves as the primary humoral regulator of platelet production.[2] It is a glycoprotein hormone produced at a relatively constant rate, primarily by hepatocytes in the liver and proximal convoluted tubule cells in the kidneys.[10] TPO exerts its biological effects by binding with high affinity and specificity to its cognate receptor, c-Mpl (also known as CD110). The c-Mpl receptor is expressed across the hematopoietic lineage, from primitive hematopoietic stem cells to megakaryocyte progenitors and, importantly, on the surface of mature, circulating platelets.[10] The binding of TPO to c-Mpl on progenitor cells is the critical initiating signal that drives the proliferation, differentiation, and ultimate maturation of megakaryocytes—the large, polyploid bone marrow cells that undergo cytoplasmic fragmentation to release thousands of platelets into the circulation.[10]

Pathophysiological Basis of Thrombocytopenia

Thrombocytopenia, a condition characterized by a clinically significant reduction in platelet count (typically below 150 platelets/nl), can arise from two principal mechanisms: impaired platelet production in the bone marrow or accelerated destruction of platelets in the periphery.[18] In Primary Immune Thrombocytopenia (ITP), an acquired autoimmune disorder, the pathophysiology is twofold. Autoantibodies are generated that opsonize platelets, leading to their premature clearance by macrophages in the spleen and liver. Concurrently, these autoantibodies can also target megakaryocytes in the bone marrow, impairing their maturation and platelet production. A critical feature of ITP is that, despite the low platelet mass, endogenous TPO levels are often inappropriately low or only slightly elevated. This creates a state of relative TPO deficiency, where the bone marrow does not receive an adequate compensatory stimulus to ramp up platelet production. This observation provides a compelling biological rationale for the therapeutic administration of exogenous TPO or its agonists.[1] In contrast, Chemotherapy-Induced Thrombocytopenia (CIT) is a direct consequence of the myelosuppressive effects of cytotoxic agents, which damage hematopoietic progenitors in the bone marrow, leading to a primary failure of production.[8]

The Unmet Clinical Need for Effective Thrombopoietic Agents

Severe thrombocytopenia places patients at a significant risk of bleeding, ranging from mild mucocutaneous bleeding to life-threatening intracranial hemorrhage.[19] In the oncological setting, CIT frequently necessitates chemotherapy dose reductions, treatment delays, or discontinuation of therapy, which can compromise the efficacy of cancer treatment.[20] The standard supportive care measure for severe thrombocytopenia has historically been the transfusion of platelet concentrates. However, this approach has notable limitations, including the risk of transfusion reactions, transmission of infectious agents, alloimmunization leading to refractoriness, and the transient nature of the platelet count increase.[11] These challenges underscore the profound clinical need for therapeutic agents that can stimulate the body's own platelet production in a durable and controlled manner.

The Evolution of TPO-Based Therapeutics

The cloning of the TPO gene in 1994 ushered in an era of targeted drug development aimed at harnessing this powerful physiological pathway.[2] The initial therapeutic candidates were recombinant forms of TPO. One of the first to enter extensive clinical trials was a truncated, N-terminal domain of TPO that was produced in bacteria and conjugated to polyethylene glycol (PEG-rHuMGDF).[1] While this agent demonstrated potent thrombopoietic activity, its development was abruptly halted after healthy volunteers in clinical trials developed neutralizing autoantibodies. These antibodies not only bound to the drug but also cross-reacted with and neutralized the volunteers' own endogenous TPO, resulting in severe and prolonged thrombocytopenia.[10]

This pivotal and adverse clinical event had a chilling effect on the field and fundamentally altered the trajectory of TPO-RA development. It established a high regulatory bar for immunogenicity and safety, leading to a bifurcation in development strategies. One path focused on creating molecules that could activate the c-Mpl receptor but were structurally unrelated to native TPO, thereby eliminating the risk of generating cross-reactive antibodies. This strategy led to the successful development of the peptibody romiplostim and the small-molecule agonist eltrombopag.[10] The other, more challenging path involved re-engineering a recombinant protein that would not elicit a harmful immune response. The development of rhTPO, the subject of this report, represents the successful culmination of this second strategy. By producing a full-length, glycosylated protein in a mammalian expression system, developers created a molecule that more faithfully mimics the native human hormone, thereby circumventing the immunogenicity pitfalls that doomed its predecessors.[1]

2.0 Molecular Profile and Physicochemical Properties

Drug Identification and Biochemical Description

Recombinant Human Thrombopoietin (rhTPO), registered under DrugBank Accession Number DB16364, is a biotechnologically derived therapeutic protein.[25] It is also commonly referred to by the synonyms rHuTPO and recombinant human TPO.[20] The defining characteristic of rhTPO is that it is a

full-length, glycosylated polypeptide designed to be biochemically and physiologically identical to endogenous human thrombopoietin.[1]

This high degree of fidelity to the native hormone is achieved through its production process. rhTPO is manufactured using recombinant DNA technology within a mammalian expression system, specifically Chinese hamster ovary (CHO) cells.[1] The use of a mammalian cell line is a critical design feature, as it enables the complex post-translational modifications, particularly glycosylation, that are essential for the protein's structure, stability, and biological function.

Structurally, rhTPO mirrors the 332 amino acid sequence of the mature, native human TPO protein.[26] The protein is organized into two distinct functional domains:

1. N-Terminal Domain: This region, comprising approximately the first 153 to 155 amino acids, shares significant sequence homology with erythropoietin (EPO) and contains the high- and low-affinity binding sites necessary for interaction with the c-Mpl receptor. This domain is responsible for the molecule's entire biological activity.[10]
2. C-Terminal Domain: The remainder of the polypeptide chain constitutes the C-terminal domain, which is characterized by the presence of multiple sites for N-linked and O-linked glycosylation.[16] This heavily glycosylated region does not participate directly in receptor binding but is indispensable for the protein's overall properties. It plays a crucial role in ensuring efficient secretion from the host cell, maintaining conformational stability, extending the protein's in vivo half-life, and, most importantly, reducing its immunogenic potential.[1]

Molecular Weight and Structural Distinctions

The molecular weight of rhTPO reflects its complex glycoprotein nature. The predicted molecular mass of the 332-amino acid polypeptide backbone alone is approximately 37.6 kDa.[17] However, the extensive carbohydrate side chains added during post-translational glycosylation contribute substantially to the molecule's total mass. Consequently, when analyzed by SDS-PAGE, the fully glycosylated rhTPO migrates as a much larger protein, with an apparent molecular weight in the range of 78.2 kDa to 85 kDa.[17]

It is essential to distinguish rhTPO from other thrombopoietin receptor agonists, as their structural differences underlie their distinct pharmacological properties and historical development paths.

• PEG-rHuMGDF: This was a first-generation agent consisting only of the truncated N-terminal domain (the first 163 amino acids). It was produced in E. coli, a bacterial system that cannot perform glycosylation, and was chemically conjugated to a polyethylene glycol (PEG) moiety to extend its half-life. The absence of the C-terminal domain and its associated glycosylation is widely believed to be the reason for its high immunogenicity, which led to its clinical failure.[1]
• Romiplostim (Nplate®): This agent is classified as a "peptibody," a type of recombinant fusion protein. It is composed of a human IgG1 Fc fragment, which provides a long half-life, fused to synthetic peptides that were engineered to bind to and activate the c-Mpl receptor. Crucially, these peptides have no amino acid sequence homology to endogenous TPO, a design intended to completely avoid the possibility of generating cross-reactive autoantibodies.[23]
• Eltrombopag (Promacta®/Revolade®): This agent represents a different class entirely. It is an orally bioavailable, small-molecule, non-peptide compound that activates the c-Mpl receptor by binding to a distinct allosteric site within the receptor's transmembrane domain.[23]

The selection of a mammalian CHO expression system for rhTPO was therefore not a mere manufacturing convenience but a deliberate and fundamental design choice. This decision was a direct consequence of the lessons learned from the immunogenicity failures of the bacterially-produced PEG-rHuMGDF. The developers of rhTPO correctly deduced that to create a safe and effective recombinant version of the hormone, it was necessary to replicate not only the primary amino acid sequence but also the complex post-translational glycosylation patterns of the native human protein. This glycosylation serves to "shield" potentially immunogenic epitopes on the protein surface, ensure proper three-dimensional folding, and enhance its stability in circulation. Thus, the manufacturing process is inextricably linked to the favorable clinical and safety profile of rhTPO.

The following table provides a consolidated summary of the key molecular and physicochemical properties of rhTPO.

Attribute	Description	Source Snippets
Drug Name	Recombinant Human Thrombopoietin (rhTPO)	20
DrugBank ID	DB16364	25
Type	Biotech, Recombinant Protein	25
Structure	Full-length, 332 amino acid polypeptide analogous to endogenous human TPO. Comprises an N-terminal EPO-like receptor-binding domain and a C-terminal domain.	26
Source/Expression System	Recombinant expression in Chinese hamster ovary (CHO) cells.	1
Post-Translational Modifications	Heavily glycosylated (N- and O-linked carbohydrate chains), primarily in the C-terminal domain.	16
Predicted Molecular Mass (Polypeptide)	Approx. 37.6 kDa	17
Apparent Molecular Mass (Glycosylated)	Approx. 78.2-85 kDa	17

3.0 Mechanism of Action and Pharmacodynamics

Receptor Binding and Signal Transduction

Recombinant Human Thrombopoietin functions as a direct and potent agonist of the thrombopoietin receptor, c-Mpl.[1] Its mechanism of action faithfully recapitulates that of its endogenous counterpart. rhTPO binds to the extracellular domain of the c-Mpl receptor, which is thought to exist as a pre-formed, inactive dimer on the cell surface. This binding event induces a critical conformational change in the receptor complex, leading to its homodimerization and subsequent activation of associated intracellular signaling molecules.[1] This mode of activation, involving the natural ligand-binding site on the extracellular portion of the receptor, is a key point of distinction from small-molecule TPO-RAs like eltrombopag, which bind allosterically to the receptor's transmembrane domain to induce a similar, but not identical, activating conformational change.[3]

Upon activation of the c-Mpl receptor, a coordinated network of downstream signaling pathways is engaged, driving the cellular responses that constitute thrombopoiesis.[3] The principal signaling cascades initiated by rhTPO include:

• The JAK/STAT Pathway: This is a primary and essential pathway for cytokine receptor signaling. Upon receptor dimerization, Janus kinase 2 (JAK2) molecules associated with the intracellular domains of the receptor are brought into close proximity, allowing them to trans-phosphorylate and activate each other. Activated JAK2 then phosphorylates tyrosine residues on the receptor itself, creating docking sites for Signal Transducer and Activator of Transcription (STAT) proteins, particularly STAT5. Once recruited, STATs are phosphorylated by JAK2, causing them to dimerize, translocate to the nucleus, and act as transcription factors to regulate the expression of genes involved in cell proliferation and differentiation.[1]
• The MAPK Pathway: The mitogen-activated protein kinase pathway, including the well-characterized extracellular signal–regulated kinase (ERK1/ERK2) cascade, is also robustly activated. This pathway plays a central role in transmitting signals from the cell surface to the nucleus to promote cell growth, proliferation, and survival.[1]
• The PI3K/AKT Pathway: The phosphatidylinositol 3-kinase (PI3K)/AKT pathway is another critical signaling axis engaged by rhTPO. This pathway is a major mediator of cell survival signals, primarily through its role in inhibiting apoptosis (programmed cell death).[3]

Pharmacodynamic Effects on Hematopoiesis and the Immune System

The integrated output of these signaling cascades results in a profound and specific pharmacodynamic effect on the process of megakaryopoiesis and thrombopoiesis.[10] The action of rhTPO is comprehensive, influencing every stage of platelet development:

• Stem Cell and Progenitor Proliferation: rhTPO provides a potent stimulus for the expansion of early hematopoietic progenitors, including colony-forming units-granulocyte, erythrocyte, monocyte, megakaryocyte (CFU-GEMM), and more committed megakaryocytic progenitors like burst-forming units-megakaryocyte (BFU-meg) and colony-forming units-megakaryocyte (CFU-meg).[16]
• Inhibition of Apoptosis: A fundamental mechanism of TPO action is the delivery of a powerful survival signal to its target cells. By inhibiting apoptosis, rhTPO ensures that a larger cohort of progenitor cells survives to enter the maturation pathway.[3]
• Differentiation and Maturation: rhTPO guides the differentiation of megakaryocyte precursors and drives their maturation. This process involves multiple rounds of endomitosis, where the cell undergoes DNA replication without cell division, resulting in the characteristic large, polyploid megakaryocytes.[1]
• Thrombopoiesis: Finally, rhTPO promotes the terminal stage of maturation, where megakaryocytes extend proplatelet processes that fragment into thousands of fully functional platelets, which are then released into the bloodstream.[1]

In addition to its well-defined role in hematopoiesis, evidence suggests that rhTPO also possesses immunomodulatory properties. Studies have indicated that TPO-RAs can lead to an increase in the population of regulatory T cells (Tregs), a subset of T cells crucial for maintaining immune tolerance and suppressing autoimmune responses. This effect is thought to be mediated by transforming growth factor-β (TGF-β), a cytokine that is found in high concentrations in megakaryocytes and platelets and is known to promote Treg differentiation.[1]

The mechanism of rhTPO is therefore not a simple command to "make more platelets." It is a multifaceted biological intervention that orchestrates the entire platelet production line, starting with the survival and expansion of the earliest hematopoietic stem cells and culminating in the release of functional platelets. Simultaneously, its ability to modulate the immune system may provide an additional therapeutic benefit, particularly in autoimmune disorders like ITP. This pleiotropic yet lineage-focused activity explains its broad utility across different etiologies of thrombocytopenia. It can address the primary production defect seen in CIT, while also tackling the combined defect of impaired production and immune-mediated destruction that characterizes ITP. This comprehensive biological impact provides a more nuanced understanding of its therapeutic potential than viewing it as a simple "platelet growth factor."

4.0 Clinical Pharmacology and Pharmacokinetics

General Pharmacokinetic Characteristics

The pharmacokinetic profile of Recombinant Human Thrombopoietin is characteristic of a large therapeutic protein whose disposition is governed by its interaction with a specific, high-affinity receptor. Preclinical studies have consistently demonstrated that rhTPO exhibits non-linear pharmacokinetics.[31] This non-linearity arises from the fact that a significant portion of the drug's clearance is mediated by its target receptor, a process known as target-mediated drug disposition (TMDD).

Absorption, Distribution, Metabolism, and Excretion (ADME)

• Absorption: rhTPO is formulated for parenteral administration, typically via subcutaneous injection.[1] Following subcutaneous administration, the drug is absorbed into the systemic circulation. Pharmacokinetic studies in rhesus monkeys have estimated the bioavailability of subcutaneously administered rhTPO to be approximately 50%.[33]
• Distribution: The distribution of rhTPO is influenced by its binding to the c-Mpl receptor. Preclinical investigations in rats have shown that the volume of distribution at steady-state (Vss) is dose-dependent, decreasing as the administered dose increases.[31] This phenomenon is a hallmark of TMDD. At lower concentrations, a larger proportion of the drug is bound to the high-affinity c-Mpl receptors on platelets and megakaryocytes throughout the body, leading to a larger apparent volume of distribution. As the dose increases and these receptors become saturated, a larger fraction of the drug remains free in the plasma, resulting in a smaller apparent Vss. Studies in mice using radiolabeled rhTPO have provided insights into its tissue distribution, revealing relatively high concentrations in the bone marrow (the primary site of action) and the urinary system (a key route of elimination), while penetration into the central nervous system is minimal, with the lowest levels found in the brain.[34]
• Metabolism and Elimination: The primary pathway for the clearance of rhTPO from the body is through receptor-mediated clearance. rhTPO binds to c-Mpl receptors on the surface of platelets and megakaryocytes, is internalized into the cell, and is subsequently degraded.[10] This process is not merely a clearance mechanism but also the basis of the physiological negative feedback loop that regulates platelet homeostasis. When the total mass of platelets and megakaryocytes is high, more c-Mpl receptors are available to bind and clear TPO from the circulation, leading to lower TPO levels and a reduction in thrombopoietic stimulus. Conversely, in a state of thrombocytopenia, the reduced platelet and megakaryocyte mass leads to decreased TPO clearance, resulting in higher circulating TPO levels that stimulate the bone marrow to produce more platelets.[10] The main route for the excretion of rhTPO and its metabolites is the urinary system. In a murine study, approximately 98% of a radiolabeled dose of rhTPO was excreted via the urine within 72 hours.[34]
• Half-Life: The terminal elimination half-life (t1/2) of rhTPO is also dose-dependent, a direct consequence of its non-linear, receptor-mediated clearance. In rats, reported half-life values have ranged from 6.1 to 13.2 hours, varying with the dose administered.[31] In rhesus monkeys, a longer terminal half-life of 12-18 hours has been observed.[33] Early clinical data in humans suggested a half-life in the range of 24-40 hours, which is comparable to the 20-30 hour half-life of endogenous TPO.[16] The heavily glycosylated C-terminal domain of the rhTPO molecule is structurally critical for maintaining this relatively long circulating half-life, protecting it from rapid clearance and degradation.[1]

Pharmacodynamics and Dose-Response Relationship

The pharmacodynamic effect of rhTPO—an increase in platelet count—is directly related to the administered dose. Clinical and preclinical studies have established a clear dose-response relationship, with higher doses of rhTPO leading to a more rapid and more pronounced elevation in platelet counts.[4] However, the onset of this effect is inherently delayed due to the underlying biology of thrombopoiesis. The entire process, from the stimulation of a hematopoietic stem cell to the maturation of a megakaryocyte and the subsequent release of platelets, takes approximately 10 days.[16] Consequently, a rise in peripheral platelet counts is typically observed several days after the initiation of rhTPO therapy, with peak effects in animal models occurring around day 5-6 and clinically significant increases in humans being evident by day 7 to 14 of treatment.[1]

The non-linear, receptor-mediated pharmacokinetics of rhTPO carries significant clinical implications for dosing strategies. The drug's clearance rate is inversely proportional to the severity of thrombocytopenia; a patient with a very low platelet count will clear the drug more slowly, leading to greater drug exposure and a more potent effect from a given dose. As the platelet count recovers, the clearance rate increases, naturally attenuating the drug's effect. This inherent self-regulating feature may contribute to the drug's safety profile, but it also means that a fixed-dose regimen is unlikely to be optimal for all patients. This pharmacokinetic behavior necessitates the use of a dynamic, response-guided dosing strategy, where the dose and frequency of administration are carefully titrated based on serial platelet count monitoring. This approach, which is reflected in the design of clinical trial protocols for TPO-RAs, is essential to achieve and maintain the therapeutic target platelet count while avoiding potential complications of excessive stimulation, such as thrombocytosis.[5]

5.0 Clinical Development and Therapeutic Efficacy

The clinical development program for Recombinant Human Thrombopoietin has been extensive, primarily focused within China, and has established its efficacy and safety across a range of thrombocytopenic disorders. The following table provides a high-level overview of key clinical trials that have defined its therapeutic applications.

NCT Identifier	Phase	Indication(s)	Purpose	Status	Key Findings/Notes	Source Snippets
NCT01805648	3	Immune Thrombocytopenia (ITP)	Treatment	Unknown Status	Designed to evaluate the efficacy and safety of maintenance treatment with rhTPO in patients with ITP.	37
NCT05944809	2	Thrombocytopenia, Esophageal Cancer (post-chemoradiotherapy)	Prevention	Completed	Investigated the use of prophylactic rhTPO to prevent thrombocytopenia in patients undergoing concurrent chemoradiotherapy.	38
NCT01319669	2/3	Non-Small Cell Lung Carcinoma (NSCLC)	Treatment	Terminated	Aimed to evaluate rhTPO for the prevention of thrombocytopenia following first-line chemotherapy in NSCLC.	39
NCT04324060	N/A	Lower-Risk Myelodysplastic Syndrome (LR-MDS)	Treatment	N/A	A proof-of-concept study showing that rhTPO accelerates early platelet response and reduces transfusion needs in LR-MDS.	11
NCT02391272	N/A	ITP in Pregnancy	Treatment	N/A	Observational study demonstrating that rhTPO is a potentially safe and effective option for pregnant patients refractory to standard therapies.	5
NCT06955858	N/A	Mobilization of hematopoietic stem cells	Other	Not Yet Recruiting	A planned clinical study to assess the role of rhTPO in hematopoietic stem cell mobilization for autologous transplantation.	40

5.1 Primary Immune Thrombocytopenia (ITP)

Primary Immune Thrombocytopenia represents the most well-established therapeutic indication for rhTPO. Its use is supported by a substantial body of clinical evidence, leading to its recommendation as a second-line therapy in Chinese national treatment guidelines.[1]

Adult ITP

In adult patients with ITP who are refractory to or have relapsed after first-line treatments such as corticosteroids and intravenous immunoglobulin (IVIg), clinical trials have consistently demonstrated that rhTPO can rapidly and effectively increase platelet counts to safe levels, thereby reducing the risk of bleeding.[1] A significant focus of recent clinical research has been on optimizing the dosing regimen to maximize efficacy. The conventional dose has been established at 300 U/kg per day, often administered as a fixed dose of 15,000 U/day.[1] However, clinical experience has suggested that this dose may be insufficient for some patients, leading to a delayed onset of action and a high rate of relapse upon treatment discontinuation.[1]

To address this, higher-dose regimens have been investigated. A large retrospective study directly compared a low-dose group (15,000 U/day) with a high-dose group (30,000 U/day). The results were compelling: the high-dose regimen was associated with a significantly higher total effective rate (91.8% vs. 70.5%), a markedly better response at day 7 of treatment (73.8% vs. 38.6%), and a shorter average duration of treatment. Importantly, this enhanced efficacy was achieved without a corresponding increase in the incidence of adverse events.[1] Further elucidating the dose-response relationship, a multicenter, randomized controlled trial evaluated four different regimens. This study found that a regimen of 15,000 U administered once daily (QD) for 14 days yielded the highest median increase in platelet count at the 14-day endpoint. In contrast, a regimen of 30,000 U administered once every other day (QOD) for 7 injections was found to be most effective for achieving a rapid increase in platelet counts within the first 7 days of therapy, offering a more convenient dosing schedule.[18]

Pediatric ITP

The use of rhTPO in the pediatric population has also been formally established. In April 2024, the NMPA in China granted approval for rhTPO (marketed as TPIAO®) for the treatment of persistent or chronic ITP in children and adolescents.[6] This approval was based on the results of a pivotal Phase III, multicenter, randomized, double-blind, placebo-controlled trial conducted in patients aged 6 to 17 years. The trial unequivocally demonstrated the superiority of rhTPO over placebo. The primary endpoint, the total response rate, was achieved by 58.5% of patients in the rhTPO treatment arm, compared to only 13.3% in the placebo arm, a statistically and clinically significant difference.[43]

ITP in Pregnancy

Managing severe ITP during pregnancy presents a unique clinical challenge, as some therapies may pose risks to the developing fetus. rhTPO has emerged as a promising therapeutic option in this specific and vulnerable population, particularly for patients who are refractory to standard therapies.[5] A key advantage of rhTPO in this setting is its molecular size and structure; unlike the smaller TPO-RAs eltrombopag and romiplostim, rhTPO does not appear to cross the placental barrier, minimizing the potential for fetal exposure.[18] An observational study involving 31 pregnant patients with severe, refractory ITP reported a response rate of 74.2% with rhTPO treatment. Crucially, in a median follow-up of 53 weeks, no congenital abnormalities or developmental delays were observed in the infants born to these mothers.[5] A multicenter clinical study (NCT03492515) has been designed to further and more rigorously evaluate the efficacy and safety of rhTPO in this population.[44]

5.2 Chemotherapy-Induced Thrombocytopenia (CIT)

rhTPO is approved by the NMPA for the treatment of CIT in adult patients with solid tumors.[6] Clinical studies have shown that its administration following chemotherapy can significantly reduce the severity (nadir) and duration of thrombocytopenia, accelerate platelet recovery, and consequently decrease the need for supportive platelet transfusions.[2]

While its application in patients with hematological malignancies is currently considered off-label in China, emerging evidence supports its efficacy in this setting as well. A prospective, observational study in patients with aggressive lymphoma investigated the optimal timing for initiating rhTPO. The study found that early intervention—administering rhTPO when platelet counts fell into the range of 25-75x109/L—resulted in significantly better platelet recovery and a lower incidence of platelet transfusions compared to a strategy of waiting until the platelet count dropped to severely low levels (≤25x109/L).[7] The clinical trial landscape for rhTPO in CIT includes a completed Phase 2 trial (NCT05944809) that investigated its prophylactic use in esophageal cancer patients undergoing chemoradiotherapy.[38] However, a separate Phase 2/3 trial (NCT01319669) in non-small cell lung cancer was terminated, highlighting the complexities of drug development in this indication.[39]

5.3 Other Hematological Disorders

The therapeutic potential of rhTPO extends beyond ITP and CIT to other bone marrow failure states.

• Severe Aplastic Anemia (SAA): In SAA, where hematopoietic stem cells are depleted, rhTPO has been studied as an adjunctive therapy to standard immunosuppressive therapy (IST). A comparative study demonstrated that the addition of rhTPO to an IST regimen promoted a more robust recovery of hematopoiesis. Patients receiving rhTPO exhibited an elevated number of bone marrow megakaryocytes and achieved transfusion independence for both platelets and red blood cells more quickly than patients who received IST alone.[45]
• Myelodysplastic Syndromes (MDS): In patients with lower-risk MDS (LR-MDS), thrombocytopenia is a common and challenging clinical problem. A proof-of-concept study (NCT04324060) evaluated the use of short-term rhTPO in this population. The study found that rhTPO treatment accelerated the early recovery of platelet counts and significantly reduced the need for platelet transfusions. Importantly, this was achieved without evidence of significant side effects or an increased risk of disease progression to higher-risk MDS or acute leukemia.[11] This finding is particularly relevant given the concerns about the potential for long-term use of other TPO-RAs to promote bone marrow fibrosis or clonal evolution in MDS.[11]

5.4 Emerging and Investigational Applications

The broad biological activity of rhTPO on hematopoietic stem and progenitor cells has prompted investigation into several novel applications.

• Hematopoietic Stem Cell (HSC) Mobilization: A new clinical study (NCT06955858) is planned to evaluate the potential of rhTPO to enhance the mobilization of hematopoietic stem cells from the bone marrow into the peripheral blood for collection and subsequent autologous transplantation in patients with acute leukemia. This represents a novel potential application for the drug.[40]
• Sepsis-Related Thrombocytopenia: In the critical care setting, thrombocytopenia is a common complication of sepsis and is associated with poor outcomes. rhTPO has been shown to effectively increase platelet counts in septic patients. Mechanistically, it may also inhibit the excessive platelet activation and sequestration that contribute to the pathophysiology of sepsis, potentially leading to improved outcomes such as shorter ICU stays.[46]
• Acute-on-Chronic Liver Failure (ACLF): Patients with advanced liver disease often have severe thrombocytopenia due to both decreased TPO production by the failing liver and splenic sequestration. A prospective, open-label study in ACLF patients with severe thrombocytopenia found that treatment with rhTPO significantly increased platelet counts and was associated with a reduction in bleeding events, all while demonstrating a good safety profile.[48]

6.0 Safety, Tolerability, and Immunogenicity Profile

Overall Safety and Tolerability

The clinical development and extensive post-marketing experience with Recombinant Human Thrombopoietin have established a generally favorable safety and tolerability profile. Across numerous clinical trials involving diverse patient populations, including those with ITP, CIT, and other hematological disorders, the majority of treatment-related adverse events have been reported as mild in severity and transient in nature.[1]

Common and Serious Adverse Events

The most commonly reported adverse events associated with rhTPO treatment are constitutional symptoms such as fever and chills.[8] Other less frequently reported events include dizziness, fatigue, and mild pain at the subcutaneous injection site.[5] In a retrospective study that specifically compared a low-dose (15,000 U/day) with a high-dose (30,000 U/day) regimen for ITP, the incidence of adverse events was found to be low in both cohorts and, importantly, was not statistically different between the two groups (13.6% in the low-dose group vs. 9.8% in the high-dose group).[4] This suggests that dose escalation within this range does not significantly compromise the drug's safety.

As a potent thrombopoietic agent, the primary safety concern for the entire class of TPO-RAs is the potential for thromboembolic complications resulting from excessively high platelet counts (thrombocytosis).[46] Consequently, a history of thrombosis or thromboembolic disease is a standard exclusion criterion in clinical trials of rhTPO.[41] Careful monitoring of platelet counts and appropriate dose adjustments are critical to mitigate this risk.

Immunogenicity: A Key Safety Differentiator

The immunogenicity profile of rhTPO is arguably its most critical safety feature and the primary attribute that distinguishes it from the first-generation recombinant TPO molecules that failed in development. The experience with PEG-rHuMGDF, which induced the formation of high-titer, neutralizing autoantibodies against endogenous TPO, created a significant safety concern for all subsequent protein-based TPO mimetics.[10]

rhTPO was specifically designed to overcome this challenge. Its full-length structure and human-like glycosylation pattern, achieved through production in a mammalian cell system, render it significantly less immunogenic than its truncated, non-glycosylated predecessor.[1] This design has been validated in clinical studies. Investigations into the immunogenic potential of rhTPO have shown that while some patients may develop anti-TPO antibodies after multiple injections, these antibodies are typically present at a

low titer, are transient in nature, and, most importantly, do not possess neutralizing activity against either rhTPO or endogenous TPO.[1] This low immunogenicity is the cornerstone of its long-term safety profile and has allowed for its successful clinical use for nearly two decades in China.[1]

The successful mitigation of the immunogenicity risk that halted the development of earlier recombinant TPOs is a landmark achievement. This success is directly attributable to a deeper understanding of protein biochemistry and the critical role of post-translational modifications. The developers of rhTPO recognized that the immune response was likely triggered by the unnatural, truncated structure of PEG-rHuMGDF. By investing in the more complex and costly process of producing a full-length, properly glycosylated protein in CHO cells, they created a molecule that the human immune system largely recognizes as "self." This scientific and manufacturing success story is the foundation of the drug's value proposition. However, the historical memory of the PEG-rHuMGDF failure has cast a long shadow, likely contributing to the high regulatory scrutiny and a general reluctance among Western regulatory agencies like the FDA and EMA to approve new recombinant TPO proteins. This historical context helps to explain the paradoxical status of rhTPO: a drug with a long and proven track record of safety and efficacy in one major market, yet one that remains unapproved and largely unknown in others.

Contraindications

Based on the eligibility criteria used in clinical trials, contraindications for the use of rhTPO include a known history of serious allergic reactions to biologics and a history of thrombosis or significant thromboembolic disease.[41]

7.0 Comparative Analysis with Other Thrombopoietin Receptor Agonists

A Mechanistically Diverse Class of Drugs

The class of thrombopoietin receptor agonists (TPO-RAs) includes several agents with distinct molecular structures and mechanisms of receptor activation. A comparative analysis of rhTPO against the two most widely used TPO-RAs in Western markets, romiplostim and eltrombopag, reveals important differences that inform their respective clinical profiles. The fundamental distinction lies in their relationship to the natural ligand. rhTPO is a direct recombinant analog of endogenous TPO, designed to mimic its structure and function as closely as possible. In contrast, romiplostim and eltrombopag are TPO mimetics; they activate the c-Mpl receptor but are structurally unrelated to TPO.[23] Romiplostim is a peptibody that binds to the same extracellular domain as TPO, whereas eltrombopag is a small molecule that binds to an allosteric site on the transmembrane domain of the receptor.[23]

Comparative Efficacy and Safety in Pediatric ITP

A systematic review and network meta-analysis of seven randomized controlled trials in pediatric ITP provides the most robust available evidence for a head-to-head comparison of the three agents.[49] The findings of this analysis highlight a clear trade-off between efficacy and safety.

• Efficacy: The analysis ranked romiplostim as the most efficacious of the three agents for achieving an overall platelet response. The odds ratio (OR) for response versus placebo was 17.57 for romiplostim, compared to 5.34 for eltrombopag and 5.32 for rhTPO. The Surface Under the Cumulative Ranking Curve (SUCRA) score, which represents the probability of an agent being the best treatment, was 0.96 for romiplostim, indicating near certainty of it being the most potent. rhTPO and eltrombopag demonstrated comparable and statistically significant efficacy over placebo, but were less potent than romiplostim, with identical SUCRA scores of 0.52.[49]
• Safety: The hierarchy was inverted when the agents were ranked by safety, based on the incidence of serious adverse events (SAEs). rhTPO emerged as the agent with the most favorable safety profile, ranking highest with a SUCRA score of 0.78 and an OR for SAEs versus placebo of 0.28. Eltrombopag ranked second in safety with a SUCRA score of 0.66 (OR 0.68). Romiplostim, despite its superior efficacy, was associated with the highest risk of SAEs and ranked last for safety, with a SUCRA score of 0.12 (OR 3.79).[49]

Clinical Implications and Therapeutic Niche

These comparative data suggest that each TPO-RA may have a distinct clinical niche based on its unique risk-benefit profile.

• rhTPO: The combination of its rapid onset of action and superior safety profile makes it a particularly attractive option for clinical scenarios where a swift and safe increase in platelet count is paramount. This includes the management of acute bleeding episodes, use in the peri-procedural setting, and treatment of vulnerable populations such as children and pregnant women, where safety is the primary consideration.[49]
• Romiplostim: Its unparalleled efficacy positions it as a highly potent option for patients with very refractory ITP who have failed other therapies. However, its use necessitates vigilant monitoring for potential long-term adverse effects, particularly the risk of bone marrow reticulin fibrosis, which has been associated with potent, sustained megakaryocyte stimulation.[49]
• Eltrombopag: This agent offers a balanced profile, combining good efficacy with the significant practical advantage of oral administration. This makes it an excellent choice for long-term maintenance therapy, particularly for patients who prefer to avoid regular injections.[49]

In clinical practice, particularly in China where romiplostim is not available, switching between TPO-RAs is a recognized and effective strategy. Observational studies have shown that patients who experience an inadequate response or intolerance to either rhTPO or eltrombopag can often be successfully transitioned to the other agent, highlighting the clinical utility of having mechanistically distinct options available.[19]

The table below summarizes the key distinguishing features of the three leading TPO-RAs.

Feature	Recombinant Human TPO (rhTPO)	Romiplostim	Eltrombopag	Source Snippets
Molecular Structure	Full-length glycosylated protein	Peptibody (IgG1-Fc fusion protein)	Small-molecule non-peptide	1
Receptor Binding Site	Extracellular domain (mimics endogenous TPO)	Extracellular domain (competitive binding)	Transmembrane domain (allosteric)	1
Route of Administration	Subcutaneous	Subcutaneous	Oral	1
Immunogenicity	Low (non-neutralizing antibodies)	Low (no cross-reactivity with TPO)	N/A (small molecule)	1
Efficacy Ranking (Pediatric ITP)	#2 (tied)	#1	#2 (tied)	49
Safety Ranking (Pediatric ITP)	#1	#3	#2	49
Key Advantage	Rapid onset, high safety profile	Highest efficacy	Oral convenience, balanced profile	49

8.0 Regulatory Landscape and Future Perspectives

Current Global Approval Status

The regulatory status of Recombinant Human Thrombopoietin is geographically polarized, reflecting its distinct development history and the competitive landscape in different regions.

• China (National Medical Products Administration - NMPA): rhTPO, marketed under the brand name TPIAO®, is a fully approved and widely utilized therapeutic agent in China. Its approved indications are comprehensive and include:
• The treatment of primary ITP in adult patients.[1]
• The management of CIT in adult patients with solid tumors.[6]
• The treatment of persistent or chronic primary ITP in children and adolescents, an indication that was granted approval in April 2024.[6]
• United States (Food and Drug Administration - FDA): rhTPO is not approved for any indication in the United States. The TPO-RA market in the US is dominated by romiplostim (Nplate®) and eltrombopag (Promacta®), both of which have been approved for ITP for over a decade.[13] A review of the ClinicalTrials.gov database and public regulatory documents shows no evidence of an active Investigational New Drug (IND) application or ongoing pivotal trials for rhTPO intended for FDA submission.[54]
• Europe (European Medicines Agency - EMA): Similar to the US, rhTPO is not approved for use in the European Union. The approved TPO-RAs in Europe include eltrombopag (Revolade®) and romiplostim.[15] There is no indication of any current marketing authorisation application or late-stage clinical development program for rhTPO within the EMA's jurisdiction.[55]

Future Perspectives and Unmet Needs

The future trajectory of rhTPO will likely be defined by its potential expansion beyond its current indications and, more significantly, by any strategic decisions regarding its development for global markets.

• Global Development Strategy: The most critical question for the future of rhTPO is whether its developers will pursue registration in markets outside of China. Such an endeavor would represent a significant strategic and financial commitment, as it would almost certainly require new, large-scale pivotal clinical trials designed to meet the specific and rigorous standards of the FDA and EMA. The drug's extensive and long-term safety and efficacy record in China provides a strong foundation of evidence that could support such a global development program.
• Dose Optimization and Personalization: Ongoing research is needed to further refine and personalize dosing regimens for rhTPO. The evidence suggesting that higher or more frequent initial doses can lead to faster and more durable responses in ITP warrants further investigation in prospective, randomized trials. Developing optimized, response-guided dosing algorithms could further enhance its clinical utility.[4]
• Expansion into New Therapeutic Areas: The promising preliminary data for rhTPO in other hematological conditions point to significant opportunities for indication expansion. Further, well-controlled clinical trials are warranted to formally establish its efficacy and safety in:
• Severe Aplastic Anemia (SAA) and Myelodysplastic Syndromes (MDS), where it may offer a safer alternative to long-term TPO-RA use.[11]
• Hematopoietic Stem Cell (HSC) mobilization, a novel application that could improve transplantation outcomes.[40]
• The management of thrombocytopenia in critical care settings, such as in patients with sepsis or acute-on-chronic liver failure.[47]

9.0 Conclusion: Synthesis and Expert Insights

Recombinant Human Thrombopoietin (DB16364) stands as a testament to the successful application of rational protein engineering to solve a critical drug safety problem. It is a second-generation, full-length recombinant thrombopoietic growth factor that has definitively overcome the immunogenicity liabilities that led to the failure of its truncated predecessors. By faithfully mimicking the molecular structure, glycosylation, and biological function of endogenous TPO, it provides a direct, potent, and physiological stimulus for platelet production.

The clinical value of rhTPO is firmly established within its approved market in China, where it serves as a cornerstone therapy for both ITP and CIT. The comprehensive body of evidence, including recent comparative meta-analyses, helps to define a distinct and valuable clinical niche for this agent. While it may not be the single most potent TPO-RA available globally when measured by the magnitude of platelet response, its unique therapeutic profile is characterized by a compelling combination of rapid onset of action and a superior safety profile. This positions rhTPO as a potentially optimal choice for clinical situations that demand a swift increase in platelet counts with a minimal risk of adverse events. Such scenarios include the management of patients with acute, severe bleeding; peri-procedural optimization of platelet counts; and the treatment of immunologically sensitive or vulnerable populations, such as children and pregnant women.

Ultimately, rhTPO is a mature and effective biologic therapeutic that has been somewhat eclipsed on the global stage by the commercial success and entrenched market position of the structurally distinct TPO mimetics, romiplostim and eltrombopag. Its development history is a narrative of scientific refinement and perseverance, successfully addressing the critical safety flaw of immunogenicity that once threatened the entire class of recombinant TPO proteins. The primary challenge now facing rhTPO is not one of science or clinical efficacy, but rather one of global strategy and market access. Its future potential and broader impact on clinical practice will be determined by the willingness and ability of its developers to navigate the substantial regulatory and competitive hurdles that exist in Western markets. Should this path be pursued, rhTPO could offer a valuable and differentiated alternative in the global TPO-RA armamentarium, providing clinicians with a critical tool for patients in whom safety and a rapid response are the highest priorities.

Works cited

1. Full article: Efficacy and safety of high dose recombinant human thrombopoietin in the treatment of immune thrombocytopenia - Taylor & Francis Online, accessed August 27, 2025, https://www.tandfonline.com/doi/full/10.1080/09537104.2023.2271568
2. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies - PubMed, accessed August 27, 2025, https://pubmed.ncbi.nlm.nih.gov/12411315/
3. Thrombopoietin Receptor Agonists - StatPearls - NCBI Bookshelf, accessed August 27, 2025, https://www.ncbi.nlm.nih.gov/books/NBK599500/
4. Efficacy and safety of high dose recombinant human thrombopoietin ..., accessed August 27, 2025, https://pubmed.ncbi.nlm.nih.gov/37941414/
5. A novel recombinant human thrombopoietin therapy for the management of immune thrombocytopenia in pregnancy | Blood | American Society of Hematology, accessed August 27, 2025, https://ashpublications.org/blood/article/130/9/1097/36996/A-novel-recombinant-human-thrombopoietin-therapy
6. VOLUNTARY ANNOUNCEMENT Recombinant Human Thrombopoietin Injection (TPIAO®) of 3Sbio approved for pediatric ITP indication - HKEXnews, accessed August 27, 2025, https://www1.hkexnews.hk/listedco/listconews/sehk/2024/0412/2024041201145.pdf
7. Cost-effectiveness analysis of rhTPO and rhIL-11 in the treatment of chemotherapy-induced thrombocytopenia in hematological tumors based on real-world data - Annals of Palliative Medicine, accessed August 27, 2025, https://apm.amegroups.org/article/view/99613/html
8. Effectiveness and safety of recombinant human thrombopoietin on treating chemotherapy-induced thrombocytopenia: Data pool analysis of phase II/III and complement multi-center clinical trials - ResearchGate, accessed August 27, 2025, https://www.researchgate.net/publication/288719985_Effectiveness_and_safety_of_recombinant_human_thrombopoietin_on_treating_chemotherapy-induced_thrombocytopenia_Data_pool_analysis_of_phase_IIIII_and_complement_multi-center_clinical_trials
9. Clinical observation study of recombinant human thrombopoietin in the prevention of chemotherapy-induced thrombocytopenia in patients with aggressive lymphoma. - ASCO Publications, accessed August 27, 2025, https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.e19056
10. Thrombopoietin - Wikipedia, accessed August 27, 2025, https://en.wikipedia.org/wiki/Thrombopoietin
11. Recombinant Human Thrombopoietin Accelerates the Recovery of Platelet in Patients With Lower-Risk Myelodysplastic Syndrome: A Proof-of-Concept Study - Frontiers, accessed August 27, 2025, https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.721764/full
12. Optimized Recombinant Human Thrombopoietin(rhTPO) Regimen Versus Eltrombopag for Pre-Treated Patients with Primary Immune Thrombocytopenia: Interim Results from a Prospective, Multicenter, Randomized Trial (TE-ITP study) | Blood | American Society of Hematology, accessed August 27, 2025, https://ashpublications.org/blood/article/144/Supplement%201/3937/529498/Optimized-Recombinant-Human-Thrombopoietin-rhTPO
13. Nplate - accessdata.fda.gov, accessed August 27, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125268s172lbl.pdf
14. Romiplostim for the management of pediatric immune thrombocytopenia: drug development and current practice - PubMed, accessed August 27, 2025, https://pubmed.ncbi.nlm.nih.gov/31239245/
15. Revolade | European Medicines Agency (EMA), accessed August 27, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/revolade
16. Thrombopoietin: The Novel Hepatic Hormone - American Journal of Physiology, accessed August 27, 2025, https://journals.physiology.org/doi/10.1152/physiologyonline.2002.17.1.6
17. Recombinant Human TPO/Thrombopoietin Protein, 10381-H07H | Sino Biological, accessed August 27, 2025, https://www.sinobiological.com/recombinant-proteins/human-thrombopoietin-10381-h07h
18. Recombinant human thrombopoietin (rhTPO) of different dosing regimens for refractory/relapsed primary immune thrombocytopenia: a multicenter, randomized controlled trial and pharmacokinetics study - ResearchGate, accessed August 27, 2025, https://www.researchgate.net/publication/366853181_Recombinant_human_thrombopoietin_rhTPO_of_different_dosing_regimens_for_refractoryrelapsed_primary_immune_thrombocytopenia_a_multicenter_randomized_controlled_trial_and_pharmacokinetics_study
19. A Study of Eltrombopag and Recombinant Human Thrombopoietin In Primary Immune Thrombocytopenia - ClinicalTrials.gov, accessed August 27, 2025, https://cdn.clinicaltrials.gov/large-docs/51/NCT04214951/Prot_SAP_ICF_000.pdf
20. Definition of recombinant human thrombopoietin - NCI Drug Dictionary, accessed August 27, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/recombinant-human-thrombopoietin
21. Recombinant human thrombopoietin clinical development - PubMed, accessed August 27, 2025, https://pubmed.ncbi.nlm.nih.gov/11012192/
22. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies | Blood, accessed August 27, 2025, https://ashpublications.org/blood/article/100/10/3457/106321/Recombinant-human-thrombopoietin-basic-biology-and
23. Biology and Chemistry of Thrombopoietic Agents - PMC, accessed August 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2904343/
24. Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia - ASCO Publications, accessed August 27, 2025, https://ascopubs.org/doi/10.1200/JCO.18.01931
25. Recombinant Human Thrombopoietin: Uses, Interactions, Mechanism of Action - DrugBank, accessed August 27, 2025, https://go.drugbank.com/drugs/DB16364
26. Recombinant Human Thrombopoietin His (HEK-293) Protein, CF ..., accessed August 27, 2025, https://www.rndsystems.com/products/recombinant-human-thrombopoietin-his-hek-293-protein-cf_288-tph
27. Recombinant Human Thrombopoietin Protein 288-TP-005 - R&D Systems, accessed August 27, 2025, https://www.rndsystems.com/products/recombinant-human-thrombopoietin-protein_288-tp
28. Eltrombopag versus romiplostim in treatment of adult patients with immune thrombocytopenia: A systematic review incorporating an indirect-comparison meta-analysis - Research journals, accessed August 27, 2025, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0198504
29. Characteristics and down-stream effect of eltrombopag, romiplostim and endogenous thrombopoietin. - ResearchGate, accessed August 27, 2025, https://www.researchgate.net/figure/Characteristics-and-down-stream-effect-of-eltrombopag-romiplostim-and-endogenous_tbl1_332998984
30. Human TPO (Thrombopoietin) Recombinant Protein (PHC9511) - Thermo Fisher Scientific, accessed August 27, 2025, https://www.thermofisher.com/proteins/product/Human-TPO-Thrombopoietin-Recombinant-Protein/PHC9511
31. Pharmacokinetics and Pharamcodynamics of Recombinant Human Thrombopoietin Following Single Injection in Rats | Request PDF - ResearchGate, accessed August 27, 2025, https://www.researchgate.net/publication/340748013_Pharmacokinetics_and_Pharamcodynamics_of_Recombinant_Human_Thrombopoietin_Following_Single_Injection_in_Rats
32. Pharmacokinetics and Pharamcodynamics of Recombinant Human Thrombopoietin Following Single Injection in Rats | Blood | American Society of Hematology, accessed August 27, 2025, https://ashpublications.org/blood/article/112/11/5400/62981/Pharmacokinetics-and-Pharamcodynamics-of
33. Pharmacokinetics and peripheral platelet counts after a single dose of recombinant human thrombopoietin in rhesus monkeys - PubMed, accessed August 27, 2025, https://pubmed.ncbi.nlm.nih.gov/10452100
34. [Metabolism, Distribution and Excretion of Recombinant Human Thrombopoietin in Mice], accessed August 27, 2025, https://pubmed.ncbi.nlm.nih.gov/12578571/
35. Romiplostim (Nplate) - Medical Clinical Policy Bulletins - Aetna, accessed August 27, 2025, https://www.aetna.com/cpb/medical/data/700_799/0768.html
36. NPLATE® (romiplostim) for injection, for subcutaneous use - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed August 27, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125268s167lbl.pdf
37. Recombinant Human Thrombopoietin Unknown Status Phase 3 Trials for Thrombocytopenia / Immune Thrombocytopenia (ITP) Treatment - DrugBank, accessed August 27, 2025, https://go.drugbank.com/drugs/DB16364/clinical_trials?conditions=DBCOND0035132%2CDBCOND0006608&phase=3&purpose=treatment&status=unknown_status
38. Recombinant Human Thrombopoietin Completed Phase 2 Trials for Thrombocytopenia / Concurrent Chemoradiotherapy / Esophageal Cancer / Intensity Modulated Radiation Therapy Prevention - DrugBank, accessed August 27, 2025, https://go.drugbank.com/drugs/DB16364/clinical_trials?conditions=DBCOND0048154%2CDBCOND0028460%2CDBCOND0117738%2CDBCOND0006608&phase=2&purpose=prevention&status=completed
39. Recombinant Human Thrombopoietin Terminated Phase 2 / 3 Trials for Non-Small Cell Lung Carcinoma Treatment - DrugBank, accessed August 27, 2025, https://go.drugbank.com/drugs/DB16364/clinical_trials?conditions=DBCOND0030527&phase=2%2C3&purpose=treatment&status=terminated
40. Recombinant Human Thrombopoietin Not Yet Recruiting Phase Trials for Mobilization of hematopoietic stem cells Other - DrugBank, accessed August 27, 2025, https://go.drugbank.com/drugs/DB16364/clinical_trials?conditions=DBCOND0023418&phase=&purpose=other&status=not_yet_recruiting
41. Full article: Recombinant human thrombopoietin (rhTPO) of different ..., accessed August 27, 2025, https://www.tandfonline.com/doi/full/10.1080/09537104.2022.2157806
42. Recombinant human thrombopoietin (rhTPO) of different dosing regimens for refractory/relapsed primary immune thrombocytopenia: a multicenter, randomized controlled trial and pharmacokinetics study - PubMed, accessed August 27, 2025, https://pubmed.ncbi.nlm.nih.gov/36597010/
43. Efficacy and safety of recombinant human thrombopoietin for the treatment of chronic primary immune thrombocytopenia in children and adolescents: A multicentre, randomized, double-blind, placebo-controlled phase III trial - PubMed, accessed August 27, 2025, https://pubmed.ncbi.nlm.nih.gov/39267281/
44. Study Details | Recombinant Human Thrombopoietin(rhTPO) in Pregnancy With Immune Thrombocytopenia | ClinicalTrials.gov, accessed August 27, 2025, https://clinicaltrials.gov/study/NCT03492515
45. Recombinant Human Thrombopoietin Treatment Promotes Hematopoiesis Recovery in Patients with Severe Aplastic Anemia Receiving Immunosuppressive Therapy - PMC, accessed August 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4377357/
46. Efficacy and Safety of Recombinant Human ... - Frontiers, accessed August 27, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2020.00940/full
47. Efficacy and Safety of Recombinant Human Thrombopoietin on Sepsis Patients With Thrombocytopenia: A Systematic Review and Meta-Analysis - PMC, accessed August 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7344265/
48. (PDF) Efficacy of recombinant human thrombopoietin in patients with acute-on-chronic liver failure and thrombocytopenia: A prospective, open-label study - ResearchGate, accessed August 27, 2025, https://www.researchgate.net/publication/390921111_Efficacy_of_recombinant_human_thrombopoietin_in_patients_with_acute-on-chronic_liver_failure_and_thrombocytopenia_A_prospective_open-label_study
49. Comparative efficacy and safety of rhTPO, romiplostim, and eltrombopag in the treatment of pediatric primary immune thrombocytopenia: a systematic review and network meta-analysis - PubMed, accessed August 27, 2025, https://pubmed.ncbi.nlm.nih.gov/40547032/
50. Comparative efficacy and safety of rhTPO, romiplostim, and ..., accessed August 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12179062/
51. Switching between eltrombopag and recombinant human thrombopoietin in patients with immune thrombocytopenia: an observational study | Chinese Medical Journal - MedNexus, accessed August 27, 2025, https://mednexus.org/doi/10.1097/CM9.0000000000002346
52. Optimal Management of Chemotherapy-Induced Thrombocytopenia with Thrombopoietin Receptor Agonists - PMC - PubMed Central, accessed August 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10872905/
53. The Road to Romiplostim Approval and Beyond - Cancer Network, accessed August 27, 2025, https://www.cancernetwork.com/view/road-romiplostim-approval-and-beyond
54. Recombinant Human Thrombopoietin (rhTPO) in Management of Immune Thrombocytopenia (ITP) in Pregnancy | ClinicalTrials.gov, accessed August 27, 2025, https://clinicaltrials.gov/study/NCT02270801?tab=table
55. Adzynma | European Medicines Agency (EMA), accessed August 27, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/adzynma
56. A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation - PubMed, accessed August 27, 2025, https://pubmed.ncbi.nlm.nih.gov/10707996/
57. [Clinical use of recombinant human thrombopoietin. Status and perspectives] - PubMed, accessed August 27, 2025, https://pubmed.ncbi.nlm.nih.gov/11360368/